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Abstract: Throughout its known history, the gram-negative bacterium Chlamydia pneumoniae has
remained a challenging target for antibacterial chemotherapy and drug discovery. Owing to
its well-known propensity for persistence and recent reports on antimicrobial resistence within
closely related species, new approaches for targeting this ubiquitous human pathogen are urgently
needed. In this review, we describe the strategies that have been successfully applied for the
identification of nonconventional antichlamydial agents, including target-based and ligand-based
virtual screening, ethnopharmacological approach and pharmacophore-based design of antimicrobial
peptide-mimicking compounds. Among the antichlamydial agents identified via these strategies,
most translational work has been carried out with plant phenolics. Thus, currently available data
on their properties as antichlamydial agents are described, highlighting their potential mechanisms
of action. In this context, the role of mitogen-activated protein kinase activation in the intracellular
growth and survival of C. pneumoniae is discussed. Owing to the complex and often complementary
pathways applied by C. pneumoniae in the different stages of its life cycle, multitargeted therapy
approaches are expected to provide better tools for antichlamydial therapy than agents with a single
molecular target.
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1. Introduction
Since its identification as a district species in 1980s [1,2], Chlamydia pneumoniae has been recognized
as an ubiquitous human pathogen, responsible for 5%–10% of community-acquired pneumonia cases
and causing a spectrum of respiratory tract infections with varying severity. Based on serological
studies, this bacterium is currently known to be present in the populations of both developed and
developing countries and to infect the majority of people at least once in a lifetime. Within the 30 years
of research on C. pneumoniae, this small spherical bacterium has presented itself as a challenging target
for antimicrobial therapy and drug development. Inherent challenges in the antichlamydial therapy
link to the Gram-negative yet morphologically unique cell wall of Chlamydiaceae and the obligate
intracellular, intravacuolar replication of this family of bacteria. The chlamydial outer membrane
consisting of family-specific lipooligosaccharides creates a permeability barrier that typically limits the
entry of antibiotics into gram-negative bacteria. The inclusion membrane surrounding C. pneumoniae
during its intracellular stages forms an additional barrier towards antibiotics; in contrast to many
other vacuolar parasites, the Chlamydiaceae-associated inclusion membrane does not allow entry of
components with an approximate size of greater than 500 Da by passive diffusion [3]. A relatively
small size, sufficient tissue penetration and ability to pass through eukaryotic cell membranes are
therefore necessary for any therapeutic agent targeting structures of replicating Chlamydia spp. bacteria.
Microorganisms 2016, 4, 43; doi:10.3390/microorganisms4040043 www.mdpi.com/journal/microorganisms
Microorganisms 2016, 4, 43 2 of 13
In clinical settings, C. pneumoniae infections are associated with relapsing symptoms and treatment
failures even when the first-choice antibiotics are used. Up to 30% of patients with C. pneumoniae-caused
community acquired pneumonia have been reported to harbor the bacterium in a cultivable form even
after the treatment and symptoms have ceased [4,5]. According to current knowledge, chlamydial
persistence, rather than resistance, is responsible for most treatment failures. To date, no resistant
mutants of C. pneumoniae have been isolated from clinical samples and even the strains originating
from patients with treatment failure do not show altered in vitro susceptibility profiles to antibiotics.
Documentation on tetracycline resistance in a related porcine pathogen Chlamydia suis and reports
on the transfer of genetic material between chlamydial species, recently reviewed by Borel et al. [6],
demonstrate that the possibility of homotypic and heterotypic resistance must also be considered in
the future in human chlamydial infections.
In our previous review article, we have discussed the nonconventional antichlamydial agents
identified within past ten years and highlighted the need for more narrow-spectrum or even
chlamydia-specific antibacterial agents [7]. In the current contribution, we focus on describing the
different approaches for antichlamydial drug discovery, with illustrative examples of successful use
of each of them. In addition, some recent advances in the characterization and translational work on
the nonconventional antichlamydial compounds are presented. Regarding the mechanisms of action,
special emphasis is put on discussing the various cellular processes affected by both C. pneumoniae and
a potent antichlamydial agent luteolin.
2. Lead Discovery Strategies
Besides the above mentioned inherent challenges in antichlamydial therapies, discovery of new
antichlamydial agents faces some major technical limitations due to the long developmental cycle
and genetic intractability of C. pneumoniae. These features make large-scale screens of small molecule
libraries against C. pneumoniae unattractive, slow and technically demanding. Here, we describe
more focused and hypothesis-driven approaches that have proven useful in the attempts to find new
inhibitors of C. pneumoniae.
2.1. Epidemiological/Ethnopharmacological Approach
Epidemiological and ethnopharmacological approaches as the basis for finding novel bioactive
compounds stem from the observations on health-promoting effects of dietary components and herbal
remedies. As a result of long coevolution with other species, secondary metabolites of plants and
other organisms have proven to be a fruitful source of small molecules interacting and interfering with
animal and microbial cells. This is well illustrated by the fact that approximately half of currently
approved drugs are of natural origin, and biogenic drugs are especially abundant in the antimicrobial
therapy areas [8].
Connection of C. pneumoniae infection to atherosclerosis and other inflammatory diseases, along
with the well-known protective role of dietary polyphenols in these diseases, have triggered the
question on a potential link between C. pneumoniae and the phenolic compounds. Inspired by the
French paradigm, red wine extract has been shown to suppress C. pneumoniae growth [9]. In our
previous screening study of 93 Finnish plant extracts for their inhibitory effects on C. pneumonia,
several plant extracts, including blueberry, thyme and different mint species, were found to suppress
C. pneumoniae growth in an epithelial cell line [10]. Based on its high antichlamydial activity and
traditional use for treating respiratory tract symptoms, corn mint (Mentha arvensis L.) was selected for
further characterization. The antichlamydial effect of corn mint was characterized in a mouse model of
acute C. pneumoniae infection, revealing a decrease in the number of C. pneumoniae-positive animals and
C. pneumoniae-specific IgG antibodies among the extract-treated mice. Bioactivity-guided fractionation
revealed two phenolic compounds, linarin and rosmarinic acid as the main antichlamydial components
of the extract [11].
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The studies on polyphenol-rich plant extracts prompted the systematic investigation of plant
phenolics in purified form as antichlamydial agents. In a study of 57 compounds selected to cover the
typical classes of phenolic compounds, gallates, flavones and flavonoles were identified as the most
active types of the studied phenolics against C. pneumoniae clinical isolate K7 in epithelial cells [12].
The antichlamydial activity of luteolin, a flavonol present in apples, broccholi, parsley and several
other dietary plants, has also been studied in vivo using the mouse model on acute C. pneumoniae
infection, revealing similar results in a relative number of C. pneumoniae-positive animals and
C. pneumoniae-specific IgG titer as described above on the corn mint extract [13]. Luteolin and various
other dietary phenolics have been extensively studied on their cellular and molecular level activities,
and besides guiding our everyday dietary choices, the ultimate value of the identification of the
antichlamydial activities of these compounds can be seen in the insights into the intracellular survival
mechanisms that might be reached via further mechanistic studies. With this in mind, the latter part of
this review describes some of the cellular processes that are potentially involved in the interactions
between dietary phenolics and C. pneumoniae.
The potential of further mining the traditionally used medicinal plants for antichlamydial
compounds is also supported by recent findings with a reverse approach. Using a high-content
screening assay for the identification of antichlamydial compounds in a diversity-based natural product
library, schisandrin B was found to suppress C. pneumoniae growth [14]. This dibenzocyclooctadiene
lignin, together with its close structural analogues, is the dominant chemical components in the
fruit extract of Schisandra chinensis (Turcz. Baill.) commonly known as wu wei zi or five-flavour
berry, an extensively applied adaptogenic and liver-protecting medication in eastern medicine.
Among its many other uses, the S. chinensis fruit extract has been used to alleviate respiratory tract
symptoms, especially prolonged coughing [15]. The antichlamydial activity of the extract has also been
demonstrated [16], and even though the original findings were not driven by the ethnopharmacological
hypothesis, the traditional indication of the extract fits well with the typical clinical manifestation of
C. pneumoniae infections.
2.2. Target-Based Virtual Screening
Challenged by the fact that existing antibacterial drugs target only a handful of bacterial molecules,
new antibiotics with novel mechanisms of action are urgently needed. Relying on the concept of the
essential role of individual proteins in a given disease, target-based drug discovery has been at the
core of rational drug discovery for several decades. The inherent prerequisite for effective target-based
discovery is the well-validated nature of the target protein, which in the case of antimicrobial drug
discovery, reflects the indispensable role if the molecule for either microbial growth or virulence.
In the context of C. pneumoniae infections, this process is hindered by the lack of data on suitable
chlamydia-specific proteins that could be targeted to block bacterial replication or block its virulence
mechanisms. One of the few chlamydial targets with evidence on the remarkable, indispensable role
in the intracellular survival of C. pneumoniae is chlamydial protease-like activity factor (CPAF). This
chlamydial effector protein is known to be secreted from the infection vacuole once effective replication
has been established and, as its name indicates, cleave host cell proteins for the chlamydial favour [17].
In 2011, Christian et al. reported on findings demonstrating the ability of C. pneumoniae CPAF to induce
Golgi fragmentation [18]. This feature was reported to be vital for C. pneumoniae survival, allowing
the authors to conclude that targeting CPAF could be an effective strategy to suppress chlamydial
infections. In addition, CPAF has been shown to disrupt host cell proinflammatory signaling by
cleaving a NF-κB family transcription factor p65, indicating the role of CPAF as a chlamydial virulence
factor by limiting host cell sensitivity to proinflammatory stimuli [19]. CPAF crystal structure has
been resolved as a complex with a protease inhibitor lactocystin, and based on a proteomic analysis
host epithelial cells upon C. pneumoniae infection, a target recognition sequence for CPAF has been
suggested [20]. These data could provide starting points for rational design of CPAF inhibitors, but the
effectiveness of any compounds identified on CPAF can be expected to cover only acute chlamydial
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infections. Even though the role of CPAF for successful acute infection seems indispensable, the
translocation of CPAF to host cell cytoplasm is inhibited in persistent infection [17], which suggests
that targeting CPAF may not represent an effective strategy for eradication of persistent infections.
Besides the lack of validated targets, target-based drug discovery on C. pneumoniae is limited
by the fact that structural studies on C. pneumoniae proteins have focused on immunogenic surface
proteins. Thus, very limited number of 3D structures of other C. pneumoniae proteins that could be
used as the basis for docking screens of virtual small molecule libraries is available. To overcome
these limitations, a similarity-based screen of C. pneumoniae genes in other organisms, combined with
homologue modeling of the protein structure, can be applied.
Following this approach, a search for C. pneumoniae genes encoding proteins with no human
analogues but showing high similarity to other bacterial genes associated with known protein 3D
structures identified C. pneumoniae dimethyladenosine transferase (coded by the ksgA gene) as a close
homologue to a Bacillus subtilis ermC gene, encoding a RNA methyltransferase [21]. Both genes encode
for enzymes belonging to RNA (adenine-N6-)-methyltransferases (EC 2.1.1.48), mediating essential
functions in ribosomal methylation and structure. The B. subtilis ermC crystal structure was used for a
virtual screen of 300,000 compounds (Figure 1), followed by growth inhibition assays on C. pneumoniae,
with 33 compounds selected to represent the most probable ligands of the enzyme active site. Among
the 33 assayed compounds, eight previously unknown antichlamydial compounds were identified.
Further lead optimization has been carried out on compounds with a benzimidazole core structure
by the design and synthesis of new derivatives bearing this skeleton as well as structure-activity
relationship studies, demonstrating several derivatives with MIC values in low micromolar range and
indicating the favourable impact of non-planar conformation of the 2-arylbenzimidazole structure for
the antichlamydial activity [22,23].
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Figure 1. The lead optimization gives information via structure–activity relationships that will be basis
to synthesize the next generation of lead compounds.
Other studies on these benzimidazole derivatives have shown that they do not exert broad-spectrum
antibacterial activities, and despite their in silico affinity to ermC active site, their additional or
alternative molecular targets are yet to be identified in vitro.
2.3. Ligand-Based Virtual Screening
Despite the established role of target-based approaches in drug discovery over the past few
decades, this strategy has generally failed to produce new antibacterial drug candidates [24].
Massive efforts by the pharmaceutical industry have been made to evaluate the 100–200 conserved
bacteria-specific genes identified within genome sequencing projects in terms of their essentiality for
bacterial replication. Based on this work, potent small molecule inhibitors on a selection of these
targets have been identified and taken to preclinical and clinical development, resulting in mostly
disappointing outcomes and discontinuation of the projects. Even though the non-optimal properties
of the chemical libraries applied as a starting point has been identified as one contributing factor to
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the phenomenon, the reductionist target-based approach is considered to play a central role in this
overall failure. The target-based approach suffers from two major limitations: the prerequisite for
extensive target validation and the inability to reflect the complex interactions of biomolecules in a
living organism.
Owing to these factors, phenotypic screening is regaining popularity in antibacterial drug
discovery, as bacterial survival typically offers an easily detectable, biologically meaningful endpoint
for the phenotypic assays. Regarding C. pneumoniae, technical limitations in the phenotypic growth
assays exist due to the long life cycle and lack of general access to recombinant strains with fluorescent
or luminescent reporter insertions. As the throughput capacity of the in vitro screening systems is
limited, filtering chemical collections in silico is a plausible option.
The potential value of such a ligand-based virtual screening approach in finding new
antichlamydial agents is demonstrated by our recent work describing a chemical space analysis
of the previously identified plant-based antichlamydial compounds [25]. The chemometric analysis
of 19 antichlamydial compounds showed them clustering together in a multidimensional chemical
space defined by physicochemical descriptors such as size, aromaticity, polarity and lipophilicity.
The identified privileged area within chemical space was utilized for a similarity screen on a small
natural product library, allowing the selection of only 10% of the compounds for in vitro testing instead
of the whole library, by selecting only the compounds closest to the identified antichlamydial hot
spot. The in vitro C. pneumoniae growth inhibition assays revealed six new antichlamydial compounds,
including mycophenolic acid, a clinically approved drug with known antibacterial activities. Of note,
all six newly identified antichlamydial compounds are, despite sharing the same physicochemical
properties, structurally different from each other and from the reference compounds. This finding
indicates the power of this strategy in introducing more structural diversity to the lead molecules
than any conventional structure-activity relationship model does. In addition, the described approach
is generic in the sense that it is applicable to the lead discovery of also other microbes sharing
limitations in in vitro screening capacity, given that a suitable reference set can be identified. Whether
the identified privileged area in chemical space reflects a shared mechanism of action within the
antichlamydial compounds or rather represents favourable physicochemical properties for penetrating
into the chlamydial inclusion is a matter of further studies.
2.4. Pharmacophore-Based Design
Cationic antimicrobial peptides (AMPs) are a class of naturally occurring anti-infective agents
essentially contributing to the innate immunity of all multicellular organisms [26]. The antimicrobial
efficacy of most AMPs reflects their ability to disrupt bacterial membranes. Selective interaction of
these peptides to microbial membranes is explained by a higher negatively charged outer surface
and lack of cholesterol. As briefly mentioned above, most therapeutic challenges associated with
C. pneumoniae infections are associated with the propensity to persistence, and finding therapies not
relying on bacterial replication can be considered one of the ultimate goals of antichlamydial drug
discovery. AMPs with inherent activity to the gram-negative outer membranes represent a means for
also targeting C. pneumoniae in its nonreplicative form, and the potential for this approach has been
illustrated by the ability of a cathelicidin-type AMP present in leukocytes to suppress C. pneumoniae
infectivity when EBs are treated with the peptide [27].
Due to their nature as peptides, applicability of AMPs as therapeutic agents suffers from
limitations in oral bioavailability and, more generally, inability to penetrate eukaryotic cell membranes.
To overcome these challenges, a pharmacophore model for the synthesis of peptidomimetics has been
applied. Instead of specific amino acid sequences, the antimicrobial activity of AMPs can be correlated
with a given amount and topological distribution of charges, allowing the design of small molecules
fulfilling these requirements. Applying such a strategy, a series of β2,2-amino acid derivatives has been
synthesized and shown effective against both gram-negative and gram-positive bacteria [28]. These
derivatives have been found to passively diffuse through phospholipid membranes and according to
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our recently published findings, two of them are able to disrupt the C. pneumoniae replication cycle
even after the entry of the bacterium into epithelial cells [26]. Based on electron microscopy studies
and targeted administration time studies, a dual mechanism of action was proposed, involving both
destabilization of elementary bodies and targeting of the inclusion membrane in the early stages of
infection. While the impact of the β2,2-amino acid derivatives on persistent C. pneumoniae infections
is currently unexplored, these results represent the first report on AMP-derived compounds on
intracellular bacteria and demonstrate the power of pharmacophore approach in the identification of
innovative antichlamydial agents.
3. Plant Phenolics as Antichlamydial Agents
As mentioned above, the inhibitory effect of purified phenolic compounds on C. pneumoniae
growth in epithelial cells was originally reported in 2006 [12]. A relatively large proportion of the
assayed compounds were found to be highly active against C. pneumoniae (37% of the compounds
showing >80% reduction in inclusion counts), subtle structural differences were found to result in
remarkable differences in antichlamydial activity. An illustrative example on this is the difference in
C. pneumoniae infective yield when treated with quercetin and its 7-methylated analogue rhamnetin,
since rhamnetin completely blocks infective EB production at concentration 0.5 M, whereas only
partial suppression in the infective yield is seen with quercetin treatment. The same phenomenon
was later observed in a high-content screen for antichlamydial compounds among natural products,
identifying biochanin A, a methylated isoflavone as a potent inhibitor of C. pneumoniae growth [29].
Similar to the differences between methylated rhamnetin and unmethylated quercetin studied by
Alvesalo et al. [12], biochanin A was found to exert more potent antichlamydial effects than its
unmethylated counterpart genistein.
Due to the general interest of dietary phenolics as health promoting agents, a remarkable number
of studies have addressed the cellular processes affected by them. In Table 1, cellular processes affected
by luteolin, a representative example of a dietary phenolic compound with high antichlamydial activity,
are listed along with the impact of C. pneumoniae infection on the same processes. In the following
chapters, these processes are discussed in view of their relevance to the antichlamydial effects excerted
by luteolin. Excellent reviews on the signaling pathways targeted by luteolin can be found in the
literature [30–32], and instead of aiming to reproduce a comprehensive presentation of all known
aspects of luteolins biological activity, the current contribution highlights some aspects illustrating
the multifaceted and often cell-type dependent modification of eukaryotic cells seen in both luteolin
treatment and C. pneumoniae infection.
3.1. Oxidative Stress
As shown in Table 1, luteolin is known to counteract various pathological aspects reported within
C. pneumoniae infection. It is not, however, clear to what extent these activities are related to the
reduction of inclusion counts or infectious yield of the bacterium. In fact, in several cases it is not clear
whether the reported C. pneumoniae-induced processes in the host cell are crucial for bacterial survival
or rather represent innate host cell responses to the invading pathogen. As an example, C. pneumoniae
infection has been reported to increase the levels of reactive oxygen species (ROS) in various cell types,
including bronchial epithelium, platelets and macrophages [33,34]. In macrophages, Ca2+ -dependent
production of ROS and nitric oxide (NO) is linked to persistence rather than active replication [35] and
currently, there is no evidence on the role of ROS in promoting C. pneumoniae growth in epithelial cells.
In addition, ROS scavenging agents ascorbic acid and N-acetylcysteine do not suppress C. pneumoniae
growth in epithelial cells [16]. Based on these observations, it is likely that the inhibitory effects of
luteolin and other related compounds on C. pneumoniae growth in epithelial cells is not directly linked
to their ability to scavenge ROS but rather involve additional molecular targets.
Even though presumably not vital for chlamydial survival in most cell types, ROS play a central
role in the induction of the pathological consequences of C. pneumoniae infection, such as cytokine
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and chemokine production and foam cell formation [34]. Owing to their antioxidative properties,
flavonoids can thus be regarded as multifaceted antichlamydial agents, suppressing bacterial growth
and alleviating the pathophysiological consequences of the infection. This concept is supported by
the in vivo data on mice with acute C. pneumoniae infection. In this model, treatment with luteolin
significantly decreased the bacterial load in the lungs and antibody titers in the bloodstream, but also
diminished the inflammatory changes in histological samples of the lung [13]. Similar results have
also been obtained with a phenol-rich extract of corn mint [11].
3.2. Mitogen-Activated Protein Kinases
In C. pneumoniae infections, induction of mitogen-activated protein kinases (MAPK) p38,
extracellular signal regulated kinase ERK1/2 and c-Jun N-terminal kinase JNK is a well-known
consequence of the infection in various cell types [36–38]. Activation of these ubiquitous stress-related
signaling proteins is generally considered an essential step in the promotion of a proinflammatory and
often proliferative phenotype. In the context of C. pneumoniae infection, p38, ERK1/2 and JNK have
been reported to participate in different manifestations of the bacterium-induced phenotype changes
of the host cell, such as cytokine, chemokine and adhesion molecule expression [38–40], foam cell
formation [41] and increased proliferation [42,43]. Regarding C. pneumoniae entry, ERK1/2 activation
has been reported to be crucial for successful internalization of EBs, presumably participating in the
reorganization of actin microfilaments [44,45]. In these studies, C. pneumoniae entry to epithelial cells
was prevented by a small molecule inhibitor of ERK1/2 activation by its upstream activator MEK.
Luteolin, as well as several other flavonoids, are also known to suppress p38, ERK1/2 and JNK
activation in various cell types, including epithelial cells. This feature may, in part, explain the ability
of luteolin-treated epithelial cells to resist C. pneumoniae infection even in an experimental setup
in which the compounds withdrawn from culture medium prior to C. pneumoniae inoculation [12].
However, luteolin is highly active in reducing C. pneumoniae inclusion counts (MIC 9 µM) also when
administered to the infected cells 2 h post inoculation, a time point in which EB internalization has
already occurred. In the light of the current knowledge, it is not clear whether the inhibitory effect
of luteolin on MAP kinase activation is directly related to its antichlamydial properties. Several
above mentioned studies have demonstrated that small molecule inhibitors or genetic knockdown of
the MAP kinase pathways suppress C. pneumoniae-induced pathophysiological changes. However,
the impact of suppressing this signaling pathway on C. pneumoniae growth and survival in epithelial or
other cell types has remained poorly understood. With a related pathogen C. trachomatis, activation of
ERK1/2 has been reported to mediate the acquisition of host cell glycerophosholipids into chlamydial
inclusion via activation of cytosolic phospholipase A2 (cPLA2) [46]. In this study, impairment of
chlamydial growth was observed by blocking the cPLA2 activity, indicating that the pathway is
essential for C. trachomatis in lipid acquisition. Despite the relatively close phylogenetic relationship
of C. trachomatis and C. pneumoniae, differences in their ability to manipulate host cell signaling are
known to exist and one study has reported even an increase in C. pneumoniae inclusion counts upon
MEK/ERK1/2 inhibition [37].
In order to understand the role of MAP kinase signaling in C. pneumoniae growth in respiratory
epithelial cells, we have assayed commonly used p38, ERK1/2 and JNK inhibitors for their ability to
reduce C. pneumoniae inclusion counts (Figure 2). In this assay, the small molecule inhibitors were
added to the HL culture medium 2 h post inoculation in order to exclude chlamydial entry inhibition.
According to these results, the ERK1/2 pathway-targeting probes UO126 and FR180204 did not have
a remarkable effect on C. pneumoniae inclusion counts, while p38 inhibitors SB202190 and SB203580,
as well as JNK inhibitors TCSJNK60 and SP600125, were more effective in blocking C. pneumoniae
growth (unpublished data). These results indicate that especially p38 and JNK activation do seem to
have a role not only in C. pneumoniae-induced pathophysiological processes but also in the intracellular
survival of C. pneumoniae. The observation that none of these highly potent and selective probes was
able to completely prevent inclusion formation indicates, however, that chlamydial survival strategies
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involve alternative and overlapping means for inducing a suitable environment. Considering the
antichlamydial activities of luteolin and other plant phenolics, suppression of MAP kinase-driven
signaling cascades seems one possible mechanism mediating these effects.
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3.3. Intracellular Calcium Levels
Yet another cellular process, kno n to be affected by luteolin and other flavonoids and also
associated ith C. pneumoniae infection is the intracellular calciu ho eostasis. In the context of
C. pneumoniae entry into endothelial cells, genes encoding for components of Ca2+ trafficking syste
have been noted to activate within minutes of the cellular contact with the bacterium [47], and sustained,
L-type calcium channel dependent calcium ion influx has been observed in C. pneumoniae–infected
macrophages [35]. In macrophages, the elevated Ca2+ level mediates the ROS and NO production
essential for the defence against pathogenic organisms, but from C. pneumoniae point of view,
results in the persistent phenotype [48]. The studies on calcium channel blockers indicate that
their administration to C. pneumoniae-infected macrophages rescue the infection from persistence
and results in a more productive infection, and similarly, our observations on applying nonspecific
(verapamil) or L-type specific (isradipin) calcium channel blockers to infected epithelial cells support
the view that these compounds activate rather than suppress the acute infection [11]. The impact
of phenolic compounds on L-type channel mediated Ca2+ influx varies depending on compound
structure [49,50]. Of note, the phenolic compounds identified as the most potent antichlamydial
compounds in the epithelial cell model [12] do not cluster together in this respect, as luteolin and
octyl gallate, for instance, suppress Ca2+ influx while quercetin and morin stimulate it. Based on these
findings, effects on cellular calcium homeostasis are not likely associated with the suppression of
C. pneumoniae growth by phenolic compounds in epithelial cells but may, to some extent, be linked to
the differential in vivo antichlamydial activity of these compounds [13].
Besides other biological processes, the calcium modulating effects of luteolin and other flavonoids
have been linked to their ability to either induce or inhibit apoptosis in a cell type-dependent manner.
In endothelial cells, luteolin blocks Ca2+ influx upon pathogenic stimuli, protecting these cells from
apoptosis [51], whereas Ca influx into adipocytes is enhanced by luteolin treatment, leading to
mitochondria apoptotic mediator release [52]. The antiapoptotic and proapoptotic signaling affected
by luteolin also extends to various other signaling cascades, interconnecting with also those linked
to C. pneumoniae infection, such as phosphatidylinsitide-3-kinase (PI3K) pathway [53,54] and Bcl-2
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family proteins [55,56]. Similar to luteolin, the C. pneumonia-related apoptosis modulation seems
to be cell type dependent, as for instance, epithelial cells turn resistant to apoptotic signals upon
C. pneumoniae infection [57], while endothelial cells are shifted towards increased apoptotic tendency
upon the infection [58]. The significance of these cell-type dependent effects on shared pathways for
the in vitro or in vivo antichlamydial effects of luteolin remains unknown. Collectively, these features
(e.g., Table 1) illustrate the need for more holistic approaches in future discovery and characterization
of antichlamydial compounds.
Table 1. Cellular processes affected by Chlamydia pneumoniae and luteolin, a representative example of
plant phenolics suppressing C. pneumoniae growth.
Target C. pneumoniae Luteolin References
ROS + − [30,33,34]
NF-κB + − [31,39]
MAP kinases + +/− [32,36]
PI3 kinase + − [53,54]
Cytosolic Ca2+ + +/− [35–52]
Bcl-2 proteins − +/− [56,58]
“+” indicates an inducing / stimulating effect and “−“ indicates a suppressing/inhibitory effect. “+/−“
indicates that the reported effect is cell type dependent, typically with opposing effects in malignant
and nonmalignant cells. ROS = reactive oxygen species, NF-κB = nuclear factor kappaB, MAP kinase =
mitogen-activated protein kinase, PI3 kinase = phosphatidylinositide-3-kinase.
4. Models of Persistent Infection
Mostly reflecting the early phases on C. pneumoniae research involving the isolation and
characterization of bacterial strains from clinical samples, epithelial cells permissive to C. pneumoniae
have been the most widely applied host systems on this pathogen. It is, however, well recognized
that the acute infection model facilitated by centrifugation of inoculated cell monolayers does not
fully reflect the in vivo infection by C. pneumoniae, and persistence models are thus necessary for
comprehensive evaluation of any therapeutic strategies. Classically, cells of the monocyte–macrophage
lineage have been considered the main reservoir of resident persistent forms of the bacterium [59], and
these cells are thus often applied to study the spontaneous persistent infection in vitro [60]. However,
the chlamydial persistence is not limited to cells of the immune system, as the chronic infection can
be induced also in various other cell types, such as fibroblasts, smooth muscle and endothelial cells.
Different means for the induction of persistence in these cell types can be applied, such as iron or other
nutrient depletion or treatment with penicillin or interferon gamma. Recent studies on the bacterial
and host cell gene expression profiles indicate that the biological state of the infection differs depending
on the means used for persistence induction, and it is currently not clear which of the models best
represents the in vivo infection [61–63]. Besides the external inducers, a degree of persistent state can
also be triggered by a continuous infection models in epithelial cells, representing a mixed phenotype
with a proportion of the bacterial population being in an antibiotic-refractory state [64,65]. Collectively,
these models provide the means for in vitro characterization of antichlamydial compounds on different
aspects of persistence.
5. Conclusions
Faced by the poor success rate during previous decades, antimicrobial research is struggling to find
new approaches and reevaluating the old approaches to develop effective antibiotics. The examples
presented in this review show that despite the challenging features of C. pneumoniae as a drug
target, a spectrum of strategies are applicable for identifying nonconventional inhibitors of this
hard-to-treat pathogen.
Acknowledging the complexity of disease processes and living organisms in general, a shift from a
“single drug, single target” concept toward attempts to affect whole biological networks is been arising
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within biomolecular screening [66], and increased understanding on the pharmacology of classical
antibiotics also implies that their in vivo efficacy does not rely only on limiting bacterial replication,
but also on immunomodulatory and potentially other activities [67]. Combination treatments and
multifaceted therapy approaches can thus be expected to increase their popularity within antibacterials
and other therapy areas, and C. pneumoniae cannot be expected to be an exception to this phenomenon.
As illustrated by the findings on multiple interconnected and partially overlapping pathways involved
in C. pneumoniae entering epithelial cells [47] and the partial impact of inhibiting different MAP kinases
on C. pneumoniae growth presented in this contribution, C. pneumoniae likely is seldom dependent on
only one pathway or signaling cascade for its survival. Covering the complementary, alternative and
overlapping C. pneumoniae survival strategies can thus be considered vital for successful antichlamydial
agents. The various biological activities exerted by dietary phenolics make them an attractive research
topic as first generation nonconventional antichlamydial agents, but future studies are necessary to
evaluate the relevance of individual pathways in the context of C. pneumoniae infection.
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